Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/22/2008

uction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release and made by our management on the conference call, particularly those anticipating future financial performance, the results of clinical trials, the business prospects for our lead drug candidates Sulonex(TM), Zerenex(TM) and KRX-0401, our growth and operating strategies and similar matters, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete cost-effective clinical trials or meet anticipated development timelines for the drug candidates in our pipeline, including Sulonex(TM), Zerenex(TM) and KRX-0401, due to recruitment, clinical trial results, or manufacturing capabilities; our ability to finalize the new drug application for Sulonex before year-end, even if we receive positive results from the Phase 3 study, for various reasons including the completion of necessary non-clinical studies; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This pres
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
2. Keryx Biopharmaceuticals Announces Additions to Management Team
3. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
8. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)...   SunTrust Robinson Humphrey (STRH) today ... its equity research team in biotechnology and oilfield ... equity research demonstrates our commitment to providing our ... their investment decision making," said Biff Woodruff ... to make significant investments in differentiated content at ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/27/2014)... Utah (PRWEB) August 27, 2014 Varian ... will expand its current Salt Lake City manufacturing facility ... outside of Utah to ultimately create 1,000 new full ... years. , “Utah is home to hardworking people ... can be credited with Varian’s success in the manufacturing ...
(Date:8/27/2014)... --  MSC , a healthcare performance improvement company advancing ... of Mary Beth Loesch to President and ... preparing companies for rapid growth and market expansion, Loesch ... Corporate Development and Healthcare. In that role, she oversaw ... as corporate strategy and marketing. Previously, Loesch served as ...
Breaking Biology Technology:SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3MSC names Mary Beth Loesch President and CEO 2
... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it ... enrolment in its U.S. Phase II trial to,evaluate ... sarcomas that have metastasized to the lung., ... full enrolment of 52,patients, Oncolytics had to demonstrate ...
... engineers at the University of California, Berkeley, may be the ... hairs that allow the tiny lizard to scamper along vertical ... adhesive could one day be used to outfit a small ... from the millions of hairs covering a gecko,s toes, researchers ...
... PALO ALTO, Calif., Jan. 30 CV Therapeutics,Inc. (Nasdaq: ... fourth quarter and,year end financial results for 2007 after ... will webcast a conference call at,5:00 p.m. EST, 2:00 ... the live webcast, please log on to the Company,s ...
Cached Biology Technology:Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 2Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial 3New adhesive mimics gecko toe hairs 2New adhesive mimics gecko toe hairs 3CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008 2
(Date:8/27/2014)... Calif. , Aug. 27, 2014  WaferGen Bio-systems, ... its previously announced underwritten public offering of units of ... per unit for gross proceeds of $20 million, prior ... payable by the Company.  The shares and warrants are ... Each unit sold in the offering consists of ...
(Date:8/27/2014)... step in understanding the mysteries of the human genome ... that provide the most detailed comparison yet of how ... function. , The research, appearing August 28 in ... information encoded in the three species, genomes is "read ... into chromosomes. , The results add billions of entries ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that ... its catalogue: Law Enforcement Biometrics Market ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About Biometrics Biometrics is ... the basis of their physical or behavioral patterns. ... physiological traits such as fingerprints, face recognition, DNA, ...
Breaking Biology News(10 mins):WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... England are too hot to grow vines for making wine ... May 2008). The author, Emeritus Professor Richard Selley ... in the UK continue to rise as predicted, the Thames ... contain many vineyards, will be too hot to support wine ...
... the largest baby boom ever documented for the stock, with ... With typical annual averages of 50 to 100 million new ... puzzled by the huge increase and its ramifications for stock ... found one - healthy adults. In a study to ...
... have a unique ability to eat toxic mulberry leaves ... closer to understanding why: silkworms contain a special digestive ... Mulberry leaves contain an extremely high amount of ... and thus are potentially quite toxic. However, one type ...
Cached Biology News:Research suggests parts of UK could be too hot for wine making by 2080 2Healthy parents provide clues to survival of young haddock on Georges Bank 2
... for the use of small interfering RNA ... the RNA interference (RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... enzymatically, and then transfected into the target ...
... Schistosomal glutathione-S-transferase (GST) is commonly used ... in E. coli (1). The GSTTag sequence ... and in some cases the solubility of ... soluble, properly folded form, GSTTag fusion proteins ...
a1-Antitrypsin (human, alpha-1 AT)...
... The 7500ce meets the demands of the ... high performance from reliable, robust and simple ... detection power in the most challenging sample ... is equally suited to the toughest analytical ...
Biology Products: